The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of myopia in children. Considered a common ...
Myopia treatments include orthokeratology lenses and low-dose atropine, each with potential side effects. A case study revealed esotropia as a possible complication of atropine use in myopia ...
The FDA has accepted the New Drug Application (NDA) submitted by Sydnexis for SYD-101, a low-dose atropine drop indicated for myopia management, with a Prescription Drug User Fee Act (PDUFA) target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback